Edward C. Li, PharmD, BCOP, is Manager of Oncology Pharmacy at NCCN. In this position, he is responsible for the development of programs such as NCCN Insights Reports and NCCN Trends Surveys and assists in the development of NCCN Oncology Summits.Dr. Li received his Doctor of Pharmacy from the University of the Sciences in Philadelphia. He completed a pharmacy practice residency at the University of Wisconsin Hospital and Clinics and an Oncology Pharmacy Practice Residency at the University of Maryland School of Pharmacy. Before joining NCCN, Dr. Li was an Assistant Professor of Pharmacy Practice at Wilkes University. His research interests include the development of a paradigm to incorporate comparative effectiveness judgments into practice guidance, and quality assessment/improvement initiatives. The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of the NCCN.
Stakeholder Meeting on PDUFA V Reauthorization. U.S. Food and Drug AdministrationWeb site. Available at: http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM229610.pdf. Accessed November 8 2010.
SaglioGKimDWIssaragrisilS. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med2010;362:2251-2259.
SaglioGKimDWIssaragrisilS. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. 2010;362:2251-2259.